MedTrace Logo

Effect of COV2 Vaccine Formulation on the Ability to Generate Antibodies Against Coronavirus That Causes COVID-19

NCT07416539 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-07-22

No results posted yet for this study

Summary

This is a Phase 1a, single-country, single-centre, single-blinded, COV2 vaccine formulation randomized trial designed to investigate and compare the safety and immunogenicity of two COV2 vaccine formulations. COV2 is a nasal, investigational vaccine against COVID-19, based on a serotype 5 adenoviral vector producing modified SARS-CoV-2 spike protein.

Participants will receive one of the two COV2 formulations in two doses on Day 0 and Day 28.

This trial consists of two parts; Part 1 is a vaccination phase assessing safety and immunogenicity and Part 2 is a long-term immunogenicity follow-up assessing persistence of immune response.

Conditions

  • COVID - 19
  • SARS CoV-2

Interventions

BIOLOGICAL

COVID-19 Vaccines

COV2 vaccine given in formulation A in 2 doses as a nasal spray, 28 days between each dose.

BIOLOGICAL

COVID-19 Vaccines

COV2 vaccine given in formulation B in 2 doses as a nasal spray, 28 days between each dose.

Sponsors & Collaborators

  • Oy Medfiles Ltd

    collaborator INDUSTRY

  • Estimates OY

    collaborator UNKNOWN

  • Rokote Laboratories Finland Oy

    lead INDUSTRY

Principal Investigators

  • Seppo Ylä-Herttuala · Rokote Laboratories Finland Oy

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-02-10
Primary Completion
2026-11-30
Completion
2026-11-30

Countries

  • Finland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07416539 on ClinicalTrials.gov